Engineered neutrophil-derived exosome-like vesicles for targeted cancer therapy

dc.contributor.authorZhang Jiahui
dc.contributor.authorJi Cheng
dc.contributor.authorZhang Hongbo
dc.contributor.authorShi Hui
dc.contributor.authorMao Fei
dc.contributor.authorQian Hui
dc.contributor.authorXu Wenrong
dc.contributor.authorWang Dongqing
dc.contributor.authorPan Jianming
dc.contributor.authorFang Xinjian
dc.contributor.authorSantos Helder A.
dc.contributor.authorZhang Xu
dc.contributor.organizationfi=Turun biotiedekeskus|en=Turku Bioscience Centre|
dc.contributor.organization-code1.2.246.10.2458963.20.18586209670
dc.converis.publication-id174776743
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/174776743
dc.date.accessioned2022-10-28T13:59:39Z
dc.date.available2022-10-28T13:59:39Z
dc.description.abstractNeutrophils are the most abundant innate immune cells in human circulation; however, their derived exosomes have been rarely studied for tumor treatment. Here, we reported that exosomes from neutrophils (N-Ex) induce tumor cell apoptosis by delivering cytotoxic proteins and activating caspase signaling pathway. In addition, we decorated N-Ex with superparamagnetic iron oxide nanoparticles ( SPIONs) to achieve higher tumor-targeting therapeutic effect. We further fabricated exosome-like nanovesicles from neutrophils (NNVs) at high yield. Compared with liposome-loaded doxorubicin (DOX) and natural NNVs, DOX-loaded NNVs show an improved inhibition of tumor cell proliferation. Moreover, DOX-loaded, SPION-decorated NNVs selectively accumulate at the tumor sites under an external magnetic field, effectively restraining tumor growth and extensively prolonging the survival rate in mice. Overall, a simple and effective method to engineer N-Ex and NNVs at clinical applicable scale was developed, which enables the efficient and safe drug delivery for targeted and combined tumor therapy.
dc.identifier.olddbid185651
dc.identifier.oldhandle10024/168745
dc.identifier.urihttps://www.utupub.fi/handle/11111/41277
dc.identifier.urlhttps://www.science.org/doi/10.1126/sciadv.abj8207
dc.identifier.urnURN:NBN:fi-fe2022081154757
dc.language.isoen
dc.okm.affiliatedauthorZhang, Hongbo
dc.okm.discipline3122 Cancersen_GB
dc.okm.discipline318 Medical biotechnologyen_GB
dc.okm.discipline3122 Syöpätauditfi_FI
dc.okm.discipline318 Lääketieteen bioteknologiafi_FI
dc.okm.internationalcopublicationinternational co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherAMER ASSOC ADVANCEMENT SCIENCE
dc.publisher.countryUnited Statesen_GB
dc.publisher.countryYhdysvallat (USA)fi_FI
dc.publisher.country-codeUS
dc.relation.articlenumbereabj8207
dc.relation.doi10.1126/sciadv.abj8207
dc.relation.ispartofjournalScience Advances
dc.relation.issue2
dc.relation.volume8
dc.source.identifierhttps://www.utupub.fi/handle/10024/168745
dc.titleEngineered neutrophil-derived exosome-like vesicles for targeted cancer therapy
dc.year.issued2022

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
sciadv.abj8207.pdf
Size:
7.5 MB
Format:
Adobe Portable Document Format